Introduction
Nocturia is defined as waking at night at least once to void [1] . Although fluctuations in severity are common [2] , it can be a chronic, unremitting condition, with patients averaging several voids per night for many years. Their sleep is therefore subject to persistent, repeated interruptions, and nocturia has wide-ranging implications for patients' quality of life (QOL) [3, 4] , productivity [5] , longer-term physical and mental health [6, 7] , and possibly mortality [8] .
Several studies have reported the impact of nocturia on patients' health-related quality of life using recognized measurement tools, which are generic (e.g., 12-item Short-Form health survey) [7, 9] , or symptom-specific (e.g., Nocturia Quality of Life [N-QoL]) [10, 11] . The N-QoL is the most frequently used symptom-specific nocturia questionnaire. It was validated in a study conducted in 2004 involving only males [10] , and the content validity (i.e., whether it appropriately and comprehensively measures the concept of interest) was reexamined in a later study [12] . Nevertheless, currently there is no questionnaire assessing the impact of nocturia on QOL that meets the Food and Drug Administration's (FDA's) 2009 guidelines for validity [13] , mainly because the recall period (14 days or 1 month) is considered too long for a fluctuating disease and because the documentation for content validity is considered incomprehensible.
Valid patient self-reported assessments of disease burden and benefit of therapy are essential to evaluate the full clinical value of treatment for the patient. Rather than designing a de novo instrument, this study used the N-QoL as a basis for developing an enhanced content-valid tool in close dialogue with the FDA and its Study Endpoints and Labelling Development team. This tool-the Nocturia Impact Diary (NI Diary)-is capable of providing direct evidence of clinical benefit with reduction in the number of nocturnal voids, has a recall period of one night and day, and is to be completed for three consecutive days. Thus, it complements the 3-day voiding dairy, which is guideline-recommended for the assessment of urinary symptoms to provide a complete evaluation of patients with nocturia [14] .
This article outlines the process of development and validation of the NI Diary (see Appendix A found at http://dx.doi.org/10. 1016/j.jval.2014.06.007), which comprised three main steps:
Step 1: Development of a concept pool using the N-QoL questionnaire and data from relevant studies;
Step 2: Content validity study; and Step 3: Psychometric testing of construct validity, reliability, and sensitivity of the diary in a clinical trial. Besides the FDA patient-reported outcome guidelines, the NI Diary is consistent with recent guidelines on appropriate methods of establishing content validity, published by the International Society for Pharmacoeconomics and Outcomes Research [15, 16] and by the International Society for Quality of Life Research [17] .
Methods
Step 1: Development of a Concept Pool How and why nocturia affects patients' daily living has been explored in several qualitative studies. To ensure that the NI Diary reflects important aspects of nocturia experienced by patients, a comprehensive pool of concepts was compiled from the literature: a review of several nocturia content validity studies [12] and an original content validity study [18] . The conceptual framework of the NI Diary (Fig. 1) summarizes areas of nocturia impact derived from the content validity studies and shows the overall phrasing of items/questions and domains. Fig. 1 -Summary of detailed origin of NI draft diary instrument domains.
Step 2. List of the connection between domains in NI diary draft and the themed specific impacts based on concept elicitation studies by Abraham et al. [10] ¼ green, Mock et al. [12] (Piedmont study ¼ blue and Atlanta study ¼ red). Themed specific items in bold if mentioned in Booth et al. [18] and/or Ferring unpublished material. NI, Nocturia Impact.
interviews were conducted and transcribed by a professional interviewer.
Patients were recruited from two US placebo-controlled randomized controlled trials evaluating desmopressin orally disintegrating tablet (ODT; NCT01223937, NCT01262456) [19, 20] . Patients were either completers or dropouts, who finished the study 30 or more days before inclusion in the debriefing study. Inclusion criteria for the trials included two or more voids for three consecutive nights during screening, no major psychological problems or known alcohol/substance abuse, no work/lifestyle factors interfering with nighttime sleep, no obstructive sleep apnea or uncontrolled sleep disorders, no evidence of severe daytime voiding dysfunction, and written informed consent. The study was completed according to the Declaration of Helsinki and approved by institutional review boards.
The focus group meetings comprised four parts, in which patients were asked to 1) discuss the meaning and relevance of each question; 2) assess whether the diary adequately covers all aspects of nocturia and its related complaints (comprehensiveness); 3) evaluate the clarity of instructions and response options (e.g., terminology, phrasing, and format); and 4) complete the diary individually. Because this process was seeking to refine an existing instrument (i.e., N-QoL) rather than create a new one, patients were encouraged to suggest other areas of interest (item elicitation) to ensure that the NI Diary covered all important topics after they had discussed the relevance and importance of the draft questionnaire.
Transcripts of the cognitive debriefing were analyzed and items adjusted as appropriate in response to feedback generated by the sessions. A revised draft (version 2) was developed on the basis of responses to each of these phases. Based on advice from the SEALD team, two items exploring subpopulations were reintroduced and a Rasch analysis was conducted on the preliminary, cross-sectional data to confirm the changes into a slightly modified version 3.
Step 3: Psychometric Testing of Construct Validity, Reliability, and Sensitivity: IMPACT Study Version 3 of the NI Diary was subjected to formal psychometric testing in a double-blind, placebo-controlled, randomized, fixeddose study of desmopressin ODT (NCT01552343-denoted IMPACT Study). Patients with nocturia were recruited from the randomized controlled trials used in step 2 [19, 20] .
Patients included in the IMPACT study were responders on desmopressin (reduction Z33% in nocturnal voids after 1 month) or nonresponders on placebo (o33% reduction). A greater degree of variation in these parameters ensures a more adequate test of the correlation with objective urology end points and therefore chosen to ensure the inclusion of a broadly representative patient population.
The main objectives of this study were to assess the reliability and validity of the diary, the association between reduction in the number of nocturnal voids and mean changes in diary scores (indicating the sensitivity of the total score), and which items accounted for the main difference in the change in total NI score in the treatment versus placebo groups. Figure 2 shows the study design of the IMPACT study. Part 1 was composed of a screening period, initiated with a screening visit (visit 1) at 20 to 28 days before visit 2 (baseline). During part 1, no investigational product was given. The voiding and NI diaries were completed immediately after visit 1 (the "screening diary"), and again completed during the week before visit 2 (the "baseline diary"). These diaries were separated by a minimum 14-day period and completed on the same days of the week, over three consecutive days. The NI diaries were to be completed without influence from family or friends, and the investigator explained that there were no "right" or "wrong" answers. The voiding diaries did not include the first morning void as a nocturnal void, and the time to first void was defined as the time from going to bed with the intention of sleeping until the first nocturnal void (or until waking in the morning if there was no nocturnal void). Patients were instructed to empty their bladder before bed and to drink to satisfy thirst only.
Part 2 was the treatment period. Females were randomized to 25 mg desmopressin ODT or placebo and males to 75 mg desmopressin ODT or placebo. Randomization was stratified because of the gender-specific dosing of Nocdurna using preplanned computergenerated randomization lists. Treatment was initiated in the evening of visit 2 and subsequently taken nightly for 1 month. During the treatment period, one NI Diary and one voiding diary were completed just before the end-of-trial visit (day 29 Ϯ 3).
Statistical Methods (IMPACT Study)
The final NI Diary is a 12-item questionnaire. Responses are scored from 0 (lowest impact) to 4 (highest impact). Item 12 is a rating of overall impact, and the total score is derived by summing the scores from the core items 1 to 11 (Q1-Q11). The overall impact (Q12) and NI total scores were analyzed on the basis of a standardized scale from 0 to 100 (lowest impact-greatest impact), with raw scores standardized as follows:
Transformed score ¼ Sum of component items score Â 100 Maximum possible raw score Missing values were not imputed: Questions 1 to 11 must be completed for the diary to be included in analyses. Values were averaged over the 3-day period and included in the diary.
A sample of n ¼ 52 was required for 80% power to detect a correlation of r ¼ 0.4 between change from baseline to month 1 in nocturnal voids and change in total NI score (α ¼ 0.05, two sided). The study was not powered to show superior efficacy of desmopressin versus placebo.
The psychometric analyses to establish construct validity, reliability, and sensitivity were prospectively defined and all validation end points were tested using both classic item response theory and Rasch analysis to ensure the best possible level of validation evidence.
Results
Step 1: Development of a Concept Pool
As a result of a guidance meeting with the FDA, a comprehensive list of impacts was developed ( Fig. 1 ). This list was based on the thematic overview from Mock et al. [12] , which compiled data from three nocturia content elicitation studies. Mock et al. [12] qualitatively analyzed patient transcripts collated by two research groups (Atlanta and Piedmont) using semistructured interviews and focus groups. From the Atlanta site transcripts, 48 items and 13 thematic areas were derived; the Piedmont site reported 64 items and 12 thematic areas. Two themes identified by these groups were not present in the original N-QoL: "fear of falling at night" and "nocturia makes me feels old."
To complete the impact list for this study, data from Booth et al. were included along with data from an unpublished cognitive debriefing study to document the content validity of the N-QoL conducted by Ferring and involving five women [18] . Booth et al. isolated four important key characteristics/domains of nocturia: debilitating, frustrating, distressing, and puzzling. The data are presented in a very raw format under these four key headings. This demonstrates overall operability but without identifying specific thematic areas. Thus, this second article was used directly to feed the overall domain list, but its lack of specific thematic areas meant that it could have been used only as supporting evidence for the thematic areas of the overall domains (see step 2).
Based on the specific impact list and the additional inspiration from Booth et al. [18] and Ferring's unpublished content validity study, 14 draft NI Diary items were included in version 1, comprising four domains. Items compiled in step 1 were rephrased to be contained within a diary relating to the previous night and/or day. Possible responses were made appropriate for daily diary use: "not at all" (0), "slightly" (1), "moderately" (2), "quite a bit" (3), and "a great deal" (4) . The final conceptual model of the NI draft diary is presented in step 4.
Step 2: Cognitive Debriefing Study Twenty-three adults with nocturia participated in focus groups stratified by age and sex (Table 1) : men younger than 65 years (n ¼ 5) or 65 years or older (n ¼ 6) and women younger than 65 years (n ¼ 7) or 65 years or older (n ¼ 5). The item tracking sheet (Table 2) summarizes feedback on comprehensiveness, relevance and importance, and the response distribution for each item. Any changes made to the items (for inclusion in version 2), and a number of additional changes based on Rasch analysis and the transcripts from the focus groups, were incorporated into version 3 and are noted in Table 2 with the rationale for changes. The additional alterations were primarily based on the cognitive debriefing study but were further tested with the Rasch analysis.
Patients rated the wording and design of the NI Diary as generally acceptable and straightforward. Based on overall feedback, however, an explanation of the meaning of nocturia and a general introduction were included for future versions.
Step 3: Psychometric Testing: IMPACT Study
Of the 67 patients initially screened, 56 were randomized and included in the study-29 to placebo and 27 to desmopressin ODT (Fig. 2) . All 56 randomized patients completed the study. Patient characteristics are listed in Table 3 .
See Table 4 for an example of the two-way statistical testing and Table 5 for an overview of the psychometric tests performed, results, and interpretation.
Rasch analysis was possible to use because of the unidimentionality assumption (Table 4) . This was highly supported by the factor analysis, which indicated that the diary was unidimensional at all time points (Fig. 3 ). There were no significant differences between items that accounted for the main differences in the change in total NI score between study groups.
The NI Diary demonstrated a high degree of construct validity, with good sensitivity and stability in Rasch analysis. "Known group" assessment also demonstrated a strong ability to distinguish between patients with varying nocturia severity. The diary had high internal consistency, as shown by Cronbach's alpha and individual item-total score correlations. Sensitivity to change was supported by Pearson and partial correlations; although the correlation was relatively low, it was significant (P ¼ .018) with a large Cohen's D effect size.
Following psychometric testing, a minor change was made to item 8 (Version 4: "Were you worried about tripping or falling?") to avoid the misinterpretation that the question relates to falling asleep. This was picked up in the focus groups and also was raised as an issue by translators. Item 12 was also modified for the final version of the diary (Version 4: "Overall, to what extent does nocturia presently impact your life?") to ensure that the item assessed the daily impact of nocturia.
Establishing the point change that represents a clinically relevant difference on the NI Diary in only 56 patients is Change of "lay" to "lie." V3: Question kept in diary to include assessment of a huge problem for a small group of patients.
Specify "falling when getting up at night to use the bathroom"; many respondents could not relate to this question because it was not a concern at all.
V4: Addition of "tripping" to avoid misinterpretation of "falling" as "falling asleep."
Mþ65: "Falling when you had to get up to go to the bathroom."
(12) … were you worried that you would wake up people in the house?
Easy to understand.
12/23
Highly skewed and ceiling effect in previous Ferring RCT (NCT00477490).
Deleted. Question deleted because only half of the patients found it important and responses were highly skewed in several studies. Relates only to a subgroup of patients, creating missing data from all single-living patients.
None. Fþ65: "Very easy to understand." Relevant without alterations. Fþ65: "If there are more people living in the house, you know, if you're in the house with four or five other people, it would be very important."
Overall, to what extent … (13) … do you worry that the nocturia will get worse in the future?
Easy to understand. 20/23 Nicely distributed. None. Question is important, relevant, easy to understand, and scoring is nicely distributed.
(10) … do you worry that the nocturia will get worse in the future?
M-65: "The question is fine."
Suggested by patients in the cognitive debriefing study. Mþ65: "The question is fine."
V4: Rephrase.
V4: "presently" added to ensure recall period appropriate for diary.
Rephrase to "Does nocturia impact your life?" Asked very generally, could be asked more specifically about "quality of life" or specific aspects of life.
F-65: "I would take 'on'
out."
FDA, Food and Drug Administration; NI, Nocturia Impact; RCT, randomized controlled trial.
* Most changes were made as a result of the cognitive debriefing step. Where subsequent changes were made, the version of the diary for which they were introduced is indicated (V2, version 2 V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 -7 0 6
7.3 points. The cross-sectional split between severe and less severe nocturia at study start showed a relevant clinical difference of 8.6 to 13.6 points. Based on the data currently available, our educated guess is that a clinical difference on the NI Diary is obtained with a difference of between 7 and 10 points in diary scores. This is further supported by a recent real-life crosssectional survey [21] in which a reduction of one void (going from four to three, three to two, and two to one voids per night) generated changes in the NI Diary total score in the range of 7 to 10 points. A minimal clinically important difference of 5 points is suggested, whereas a difference of 10 points denotes a highly clinically important difference. More trials are required to explore this further and establish a proper minimal clinically important difference.
Discussion
Nocturia is a prevalent condition worldwide [22] , with a negative impact on patients' overall health and QOL, likely due to chronic sleep interruptions [7, 23, 24] . Tools to measure its impact and potential benefits of treatment, however, have hitherto been suboptimal. The NI Diary is a 12-item, unidimensional 3-day diary of the impact burden associated with nocturia. Its recall period is identical to that of the 3-day voiding diaries. The NI Diary has undergone a rigorous development and testing process and was developed in dialogue with the FDA and in line with International Society for Pharmacoeconomics and Outcomes Research and the International Society for Quality of Life Research guidelines [16, 17] . The diary evolved from the N-QoL questionnaire [10] and additional published content validity studies [12, 18] . The content validity was further strengthened in several cognitive debriefing and item elicitation focus group interviews.
Psychometric testing confirmed that the NI Diary has high construct validity, is unidimensional, is stable over time, and has high internal consistency and minimal item redundancy. The diary is sensitive to treatment effects or changes over time, with Cohen's D providing initial support for treatment sensitivity. The Pearson correlation between reduction in nocturnal voids and NI total score was numerically relatively low but statistically significant-the IMPACT trial could not be powered to demonstrate sensitivity fully; thus, additional larger studies are required as part of the iterative process that constitutes a questionnaire development process. The NI Diary showed adequate variance on most items, with a slight floor effect. The latter may cause difficulties in demonstrating a positive treatment effect in studies of therapy, though the significant Pearson correlation indicates that an association between improvement in symptoms and decreased burden was detected.
The NI Diary is available as a fully validated patient-reported outcome measure allowing clinicians and researchers to quantify the impact of nocturia on patients. It is simple, quick to complete, and available in several languages (US [English, Spanish], UK English, Spanish, French, German, Japanese). It is recommended that the NI Diary be used with the 3-day voiding diary to clarify the impact of nocturnal voiding on each individual patient and to monitor the effects of treatment. A more complete assessment of the patient's QOL, the burden imposed by nocturia, and improvements achieved by clinical management can thereby be gained.
Conclusions
The NI Diary has high content validity, construct validity, and reliability. Cohen's D analysis indicates adequate treatment sensitivity, although further studies in larger samples are required to confirm the diary's responsiveness to nocturia treatment. The NI Diary is the first nocturia impact assessment tool developed in close dialogue with the FDA and in accordance with the new FDA patient-reported outcome validation guidelines. Therefore, it represents a clinically meaningful measurement tool that should be used in conjunction with the voiding diary in cross-sectional assessments of patient burden and in assessments of changes with nocturia treatment.
